hims and hers compounded semaglutide Novo Nordisk calls out dangers of GLP-1s in new ad Novo Nordisk Shares Rise, Hims
Description
Insurance companies rarely cover semaglutide for weight management, even though clinical trials show 15% body weight reduction over 68 weeks in patients with obesity
Research continues to identify optimal GLP-1s
The protective cardiovascular effects of a GLP-1 analogue was demonstrated in a mouse model of non-diabetic angiotensin II-induced arterial hypertension
March 27, 2021
For many researchers, RETA represents one of the most interesting developments in modern peptide research and continues to attract attention across a variety of scientific disciplines
